Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2019 Universal Registration Document (Document d’enregistrement universel) for the year ended December 31, 2019 with the French market authority “Autorité des Marchés Financiers” (“AMF”). It can be consulted and downloaded (in French) on the Company’s website ( https://investors.innate-pharma.com/regulated-information/financial-reports ) and on the AMF’s website (www.amf-france.org).

Innate Pharma Files Its 2019 Universal Registration Document (Document d’Enregistrement Universel) and Its 2019 Annual Report on Form 20-F

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 19, 2020 AM in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders

Innate Pharma SA (IPHYF) CEO Mondher Mahjoubi on Q4 2019 Results - Earnings Call Transcript

Anti- CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic

First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors

INNATE PHARMA REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS UPDATE

Innate Pharma reports full year 2019 financial results and business update

Innate Pharma: An Attractive Commercial Stage Oncology Pick For 2020

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) who have received at least two lines of prior systemic therapy.

French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides.

French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides

MARSEILLE, France, Jan.  09, 2020  (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas. The Company has been in ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials. Based on these discussions, on December 13, 2019 , the Company decided to suspend enrollment of new patients in the TELLOMAK trial, except in Italy where the clinical trial has been suspended.

Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas. The Company has been in ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials. Based on these discussions, on December 13, 2019 , the Company decided to suspend enrollment of new patients in the TELLOMAK trial, except in Italy where the clinical trial has been suspended.

INNATE PHARMA PROVIDES UPDATE FROM REGULATORY AGENCIES  ON LACUTAMAB TELLOMAK TRIAL

The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.

Innate Pharma's Filing for Leukemia Drug Accepted in Europe

The drugmaker received welcome news from the European Medicines Agency.

Why Innate Pharma Shares Are Soaring Today

Shares of small-cap biotech Innate Pharma (NASDAQ: IPHA) are advancing strongly after the oncology-focused French biotech said the European Medicines Agency, or EMA, has accepted the Marketing Authorization Application for Lumoxiti.

Innate Pharma Rallies On Acceptance Of European Regulatory Application For Leukemia Drug

Innate Pharma S.A. (NASDAQ: IPHA) shares jumped on Thursday after the firm announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for Lumoxiti for adult patients with relapsed or refractory hairy cell leukemia.

Why This Hairy Cell Leukemia Treatment Could Be Big in Europe

Shares of Innate Pharma SA gained 23% in premarket trading on Thursday after the biotechnology company said the European Medicines Agency had accepted its application for leukemia treatment Lumoxiti.

Innate Pharma's stock rallies 23% on leukemia drug submission in Europe

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Lumoxiti® (moxetumomab pasudotox-tdfk), a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

News for Innate Pharma SA Stock (IPHA)